| Name | Title | Contact Details |
|---|
Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.
Sage Rutty and Co is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.